Christopher J Patterson
Overview
Explore the profile of Christopher J Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Treon S, Kotton C, Park D, Moranzoni G, Lemvigh C, Gathe Jr J, et al.
Front Immunol
. 2025 Feb;
15:1369619.
PMID: 39906744
Background: Cytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)-related respiratory failure. Bruton tyrosine kinase (BTK) is involved in...
2.
Richardson K, Castillo J, Sarosiek S, Branagan A, Flynn C, Meid K, et al.
Blood Adv
. 2024 Jan;
8(9):2133-2137.
PMID: 38237078
No abstract available.
3.
Castillo J, Branagan A, Sermer D, Flynn C, Meid K, Little M, et al.
Blood
. 2023 Nov;
143(7):582-591.
PMID: 37971194
Concurrent Bruton tyrosine kinase and BCL2 inhibition has not yet been investigated in Waldenström macroglobulinemia (WM). We performed an investigator-initiated trial of ibrutinib and venetoclax in symptomatic treatment-naïve patients with...
4.
Treon S, Patterson C, Garcia Sanz R, San Miguel J
Semin Hematol
. 2023 May;
60(2):59-64.
PMID: 37202255
No abstract available.
5.
Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera M, Hunter Z, et al.
Blood Adv
. 2022 Mar;
6(11):3332-3338.
PMID: 35255496
The SRC family kinase (SFK) HCK is transcriptionally upregulated and activated by mutated MYD88 (MYD88Mut), a key adaptor for Toll-receptor signaling. HCK activates BTK, AKT, and ERK in MYD88Mut lymphomas....
6.
Castillo J, Sarosiek S, Gustine J, Flynn C, Leventoff C, White T, et al.
Blood Adv
. 2021 Dec;
6(3):1015-1024.
PMID: 34965304
Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We...
7.
Castillo J, Allan J, Siddiqi T, Advani R, Meid K, Leventoff C, et al.
J Clin Oncol
. 2021 Nov;
40(1):63-71.
PMID: 34793256
Purpose: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells....
8.
Castillo J, Meid K, Gustine J, Leventoff C, White T, Flynn C, et al.
Leukemia
. 2021 Sep;
36(2):532-539.
PMID: 34531537
Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). The present study...
9.
Kofides A, Hunter Z, Xu L, Tsakmaklis N, Demos M, Munshi M, et al.
Hemasphere
. 2021 Jul;
5(8):e624.
PMID: 34291197
No abstract available.
10.
Treon S, Meid K, Hunter Z, Flynn C, Sarosiek S, Leventoff C, et al.
Blood
. 2021 Jul;
138(17):1535-1539.
PMID: 34289017
MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this...